Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194971 · ClinicalTrials.gov registry record
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
A clinical trial of Glioblastoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03194971: Recruiting study of Glioblastoma, sponsored by Medical College of Wisconsin.
NCT03194971 is a study of Glioblastoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03194971, a study of Glioblastoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
Primary Outcome
Tissue samples will be obtained at autopsy and stained for KI-67. Slides will then be digitized, and the number of active cells will be counted computationally.
Conditions Studied
Interventions
- OTHER Tumor samples from patients treated with TTFields at initial diagnosis.
- DEVICE Tumor samples from patients treated with TTFields at tumor recurrence.
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2027-05-31 |
What NCT03194971 shows while recruiting
NCT03194971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Tumor samples from patients treated with TTFields at initial diagnosis. is the first listed.
NCT03194971 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03194971 about?
NCT03194971 is a clinical study titled "NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy". This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
What is the current status of trial NCT03194971?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2017-06-01. Estimated completion is 2027-05-31.
What conditions does trial NCT03194971 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03194971?
The interventions under investigation include: Tumor samples from patients treated with TTFields at initial diagnosis. (OTHER), Tumor samples from patients treated with TTFields at tumor recurrence. (DEVICE).
Who is sponsoring clinical trial NCT03194971?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03194971 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03194971's enrollment target sits among peer trials
20 148th of 199 higher than 46 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI